Cite
HARVARD Citation
Farrell, S. et al. (2021). Regulatory news: Nulibry (fosdenopterin) approved to reduce the risk of mortality in patients with molybdenum cofactor deficiency type A: FDA approval summary. Journal of inherited metabolic disease. 44 (5), pp. 1085-1087. [Online].